Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study

              Author:Wiendl, Heinz   De Stefano, Nicola   Barkhof, Frederik   Montalban, Xavier   Achiron, Anat   Derfuss, Tobias   Chan, Andrew   Hodgkinson, Suzanne   Prat, Alexandre   Leocani, Letizia   Schmierer, Klaus   Sellebjerg, Finn   Vermersch, Patrick   Jin, Hulin   Jarvinen, Elina   Chudecka, Anita   Gardner, Lidia   

              Session Name:S16: MS Clinical Trials and Therapeutics  

              Topic:MS and Inflammatory Disease  

              Program Number:S16.006  

              Author Institution:University of Muenster, Muenster, Germany  Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy  VU University Medical Center, Amsterdam, Netherlands  Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain  Multiple Sclerosis Center, Sheba Academic Medical Center, Ramat Gan, Israel  University Hospital Basel, Basel, Switzerland  Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland  Ingham Institute for Applied Medical Research, University of New South Wales Medicine, Sydney, Australia  Université de Montréal, Montreal, QC, Canada  Experimental Neurophysiology Unit, Vita-Salute San Raffaele University, Milan, Italy  The Blizard Institute, Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom  Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark  Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France  the healthcare business of Merck KGaA, Darmstadt, Germany, Darmstadt, Germany  Cytel Inc. Geneva, Switzerland, Geneva, Switzerland  EMD Serono, Billerica, MA, USA, Billerica, MA  

              Efficacy of Early Ofatumumab vs Late Switch From Teriflunomide: Subgroup Analysis of the ALITHIOS Open-label Extension Study by Previous Disease-Modifying Therapy Exposure and Age

              Author:Wiendl, Heinz   Cohen, Jeffrey   Gold, Ralf   De Seze, Jerome   Robertson, Derrick   Wray, Sibyl   Sacca, Francesco   Zielman, Ronald   Azmon, Amin   King, Miriam   Fantaccini, Simone   Kappos, Ludwig   

              Session Name:P6: MS Clinical Trials  

              Topic:MS and Inflammatory Disease  

              Program Number:P6.016  

              Author Institution:University of Muenster, Muenster, Germany  Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH  Department of Neurology, St. Josef-Hospital/Ruhr-University Bochum, Bochum, Germany  University Hospital of Strasbourg, Strasbourg, France  Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL  Hope Neurology MS Center, Knoxville, TN  Department (NSRO), University “Federico II” of Naples, Naples, Italy  Novartis Pharma B.V., Amsterdam, Netherlands  Novartis Pharma AG, Basel, Switzerland  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland